Real-world data of immune tolerance induction using recombinant factor VIII Fc fusion protein in patients with severe haemophilia A with inhibitors at high risk for immune tolerance induction failure: A follow-up retrospective analysis

Manuel Carcao; Amy Shapiro; Nina Hwang; Steven Pipe; Sanjay Ahuja; Ken Lieuw; Janice M. Staber; Mark Belletrutti; Haowei Linda Sun; Hilda Ding; Michael Wang; Victoria Price; MacGregor Steele; Elisa Tsao; Jing Feng; Zahra Al-Khateeb; Jennifer Dumont; Nisha Jain

doi:10.1111/hae.14192

Real-world data of immune tolerance induction using recombinant factor VIII Fc fusion protein in patients with severe haemophilia A with inhibitors at high risk for immune tolerance induction failure: A follow-up retrospective analysis

Manuel Carcao, Amy Shapiro, Nina Hwang, Steven Pipe, Sanjay Ahuja, Ken Lieuw, Janice M. Staber, Mark Belletrutti, Haowei Linda Sun, Hilda Ding, Michael Wang, Victoria Price, MacGregor Steele, Elisa Tsao, Jing Feng, Zahra Al-Khateeb, Jennifer Dumont, Nisha Jain

科研成果: 期刊稿件 › 快报 › 同行评审

9 引用（Scopus）

源语言	英语
页（从-至）	19-25
页数	7
期刊	Haemophilia
卷	27
期	1
DOI	https://doi.org/10.1111/hae.14192
出版状态	已出版 - 1月 2021
已对外发布	是

!!!ASJC Scopus Subject Areas

遗传学（临床）
血液学

访问文件

10.1111/hae.14192

其它文件与链接

引用此

Carcao, M., Shapiro, A., Hwang, N., Pipe, S., Ahuja, S., Lieuw, K., Staber, J. M., Belletrutti, M., Sun, H. L., Ding, H., Wang, M., Price, V., Steele, M., Tsao, E., Feng, J., Al-Khateeb, Z., Dumont, J., & Jain, N. (2021). Real-world data of immune tolerance induction using recombinant factor VIII Fc fusion protein in patients with severe haemophilia A with inhibitors at high risk for immune tolerance induction failure: A follow-up retrospective analysis. Haemophilia, 27(1), 19-25. https://doi.org/10.1111/hae.14192

Real-world data of immune tolerance induction using recombinant factor VIII Fc fusion protein in patients with severe haemophilia A with inhibitors at high risk for immune tolerance induction failure: A follow-up retrospective analysis. / Carcao, Manuel; Shapiro, Amy; Hwang, Nina 等.
在: Haemophilia, 卷 27, 号码 1, 01.2021, 页码 19-25.

科研成果: 期刊稿件 › 快报 › 同行评审

Carcao, M, Shapiro, A, Hwang, N, Pipe, S, Ahuja, S, Lieuw, K, Staber, JM, Belletrutti, M, Sun, HL, Ding, H, Wang, M, Price, V, Steele, M, Tsao, E, Feng, J, Al-Khateeb, Z, Dumont, J & Jain, N 2021, 'Real-world data of immune tolerance induction using recombinant factor VIII Fc fusion protein in patients with severe haemophilia A with inhibitors at high risk for immune tolerance induction failure: A follow-up retrospective analysis', Haemophilia, 卷 27, 号码 1, 页码 19-25. https://doi.org/10.1111/hae.14192

@article{4985e9b967dc40c7b90b3ccd0ba44977,

title = "Real-world data of immune tolerance induction using recombinant factor VIII Fc fusion protein in patients with severe haemophilia A with inhibitors at high risk for immune tolerance induction failure: A follow-up retrospective analysis",

keywords = "haemophilia A, immune tolerance induction, inhibitor, recombinant factor VIII Fc fusion protein, rescue therapy, retrospective chart review",

author = "Manuel Carcao and Amy Shapiro and Nina Hwang and Steven Pipe and Sanjay Ahuja and Ken Lieuw and Staber, {Janice M.} and Mark Belletrutti and Sun, {Haowei Linda} and Hilda Ding and Michael Wang and Victoria Price and MacGregor Steele and Elisa Tsao and Jing Feng and Zahra Al-Khateeb and Jennifer Dumont and Nisha Jain",

note = "Funding Information: The views expressed in this manuscript are those of the authors and do not reflect the official policy of the Department of the Army/Navy/Air Force, Department of Defense or US Government. Manuel Carcao has received research support from Bayer, Bioverativ, a Sanofi company, CSL Behring, Novo Nordisk, Octapharma, Pfizer and Shire and participated in speaker/advisory boards for Bayer, Sanofi, Biotest, CSL Behring, Grifols, LFB, Novo Nordisk, Octapharma, Pfizer, Roche and Shire. Amy Shapiro has nothing to disclose. Nina Hwang is a consultant for Bayer, Shire, HEMA Biologics, BP and is a principal investigator for Sanofi. Steven Pipe is a consultant for Takeda, Novo Nordisk, Sanofi, CSL Behring, Pfizer, Genentech/Roche, Alnylam, ApcinteX, BioMarin, uniQure, Bayer, Freeline, Spark Therapeutics, Catalyst Biosciences and HEMA Biologics and has received research funding from Shire and Siemens. Sanjay Ahuja has received honoraria from Bayer, Shire and Sanofi and has participated in a speakers{\textquoteright} bureau for Shire and Sanofi. Ken Lieuw has nothing to disclose. Janice Staber received honoraria from Genentech, Sanofi, BioMarin, Novo Nordisk, Spark Therapeutics and Bayer. Mark Belletrutti has received honoraria from Sanofi, Octapharma, Roche and Takeda, received research support from Sanofi, Octapharma and Takeda and received investigator‐initiated study funding from Octapharma. Haowei Linda Sun has participated in advisory boards for Novo Nordisk and Octapharma and has received research funding from Octapharma. Hilda Ding is a principal investigator for Sanofi. Michael Wang is a consultant or advisor for Bayer, Sanofi, CSL Behring, Novo Nordisk, Takeda, Genentech, Catalyst Biosciences and BioMarin. Victoria Price has received research funding from Shire, Novo Nordisk and Sanofi and sat on advisory boards for Shire, Roche, Sanofi and Bayer. MacGregor Steele received honoraria from Baxter/Shire, Roche and Bayer. Elisa Tsao is an employee of Sanofi. Jing Feng was an employee of Sanofi at the time of the study. Zahra Al‐Khateeb is a former employee of Trinity Partners LLC, a consulting firm retained by Sanofi, to conduct the study on which this manuscript is based. Jennifer Dumont is an employee of and holds equity interest in Sanofi. Nisha Jain was an employee of Sanofi at the time of the study. Funding Information: This chart review was sponsored by Sanofi (Waltham, MA, USA). Medical writing and editing support were provided by Ashleigh Pulkoski‐Gross, PhD, CMPP, and Jennifer Alexander, MSc, MBA, CMPP, of JK Associates Inc., a member of the Fishawack Group of Companies (Conshohocken, PA, USA), and was funded by Sanofi. ",

year = "2021",

month = jan,

doi = "10.1111/hae.14192",

language = "English",

volume = "27",

pages = "19--25",

journal = "Haemophilia",

issn = "1351-8216",

publisher = "Wiley-Blackwell",

number = "1",

}

TY - JOUR

T1 - Real-world data of immune tolerance induction using recombinant factor VIII Fc fusion protein in patients with severe haemophilia A with inhibitors at high risk for immune tolerance induction failure

T2 - A follow-up retrospective analysis

AU - Carcao, Manuel

AU - Shapiro, Amy

AU - Hwang, Nina

AU - Pipe, Steven

AU - Ahuja, Sanjay

AU - Lieuw, Ken

AU - Staber, Janice M.

AU - Belletrutti, Mark

AU - Sun, Haowei Linda

AU - Ding, Hilda

AU - Wang, Michael

AU - Price, Victoria

AU - Steele, MacGregor

AU - Tsao, Elisa

AU - Feng, Jing

AU - Al-Khateeb, Zahra

AU - Dumont, Jennifer

AU - Jain, Nisha

N1 - Funding Information: The views expressed in this manuscript are those of the authors and do not reflect the official policy of the Department of the Army/Navy/Air Force, Department of Defense or US Government. Manuel Carcao has received research support from Bayer, Bioverativ, a Sanofi company, CSL Behring, Novo Nordisk, Octapharma, Pfizer and Shire and participated in speaker/advisory boards for Bayer, Sanofi, Biotest, CSL Behring, Grifols, LFB, Novo Nordisk, Octapharma, Pfizer, Roche and Shire. Amy Shapiro has nothing to disclose. Nina Hwang is a consultant for Bayer, Shire, HEMA Biologics, BP and is a principal investigator for Sanofi. Steven Pipe is a consultant for Takeda, Novo Nordisk, Sanofi, CSL Behring, Pfizer, Genentech/Roche, Alnylam, ApcinteX, BioMarin, uniQure, Bayer, Freeline, Spark Therapeutics, Catalyst Biosciences and HEMA Biologics and has received research funding from Shire and Siemens. Sanjay Ahuja has received honoraria from Bayer, Shire and Sanofi and has participated in a speakers’ bureau for Shire and Sanofi. Ken Lieuw has nothing to disclose. Janice Staber received honoraria from Genentech, Sanofi, BioMarin, Novo Nordisk, Spark Therapeutics and Bayer. Mark Belletrutti has received honoraria from Sanofi, Octapharma, Roche and Takeda, received research support from Sanofi, Octapharma and Takeda and received investigator‐initiated study funding from Octapharma. Haowei Linda Sun has participated in advisory boards for Novo Nordisk and Octapharma and has received research funding from Octapharma. Hilda Ding is a principal investigator for Sanofi. Michael Wang is a consultant or advisor for Bayer, Sanofi, CSL Behring, Novo Nordisk, Takeda, Genentech, Catalyst Biosciences and BioMarin. Victoria Price has received research funding from Shire, Novo Nordisk and Sanofi and sat on advisory boards for Shire, Roche, Sanofi and Bayer. MacGregor Steele received honoraria from Baxter/Shire, Roche and Bayer. Elisa Tsao is an employee of Sanofi. Jing Feng was an employee of Sanofi at the time of the study. Zahra Al‐Khateeb is a former employee of Trinity Partners LLC, a consulting firm retained by Sanofi, to conduct the study on which this manuscript is based. Jennifer Dumont is an employee of and holds equity interest in Sanofi. Nisha Jain was an employee of Sanofi at the time of the study. Funding Information: This chart review was sponsored by Sanofi (Waltham, MA, USA). Medical writing and editing support were provided by Ashleigh Pulkoski‐Gross, PhD, CMPP, and Jennifer Alexander, MSc, MBA, CMPP, of JK Associates Inc., a member of the Fishawack Group of Companies (Conshohocken, PA, USA), and was funded by Sanofi.

PY - 2021/1

Y1 - 2021/1

KW - haemophilia A

KW - immune tolerance induction

KW - inhibitor

KW - recombinant factor VIII Fc fusion protein

KW - rescue therapy

KW - retrospective chart review

UR - http://www.scopus.com/inward/record.url?scp=85096714672&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85096714672&partnerID=8YFLogxK

U2 - 10.1111/hae.14192

DO - 10.1111/hae.14192

M3 - Letter

C2 - 33210397

AN - SCOPUS:85096714672

SN - 1351-8216

VL - 27

SP - 19

EP - 25

JO - Haemophilia

JF - Haemophilia

IS - 1

ER -